Suggested remit: To appraise the clinical and cost effectiveness of rebisufligene etisparvovec within its marketing authorisation for treating mucopolysaccharidosis type IIIA.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6540
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 May 2026 | Please note that this evaluation has been rescheduled to align more closely with latest regulatory expectations. Therefore, we now anticipate that the evaluation will begin during mid-September 2026 when we will write to you about how to get involved. The deadline for submissions is expected in approximately mid-November 2026. - Note added to the project documents |
| 24 April 2026 (14:00) | Scoping workshop |
| 04 March 2026 - 01 April 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6540 |
| 04 March 2026 | In progress. Scoping commencing |
| 16 April 2025 | Referral |
| 07 February 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual